The IR team of Betuvax (Artgen Biotech group) has been nominated for Russia IPO Awards for their achievements at the Russian IPO, SPO and pre-IPO market.
The voting took place online from November 11, 2024 to January 27, 2025 at PREQVECA web-site.
The following companies have nominated in Best IR Team category: Arenadata, IVA Technologies, Positive Technologies, Softline, Ultimate Education, Betuvax, Vseinstrumenti.ru, Astra Group, Diasoft, MTS Bank, Ozon Pharmaceuticals, Promomed and Samolet. The winner award ceremony will be held at IPO-2025 conference on February 27, 2025 in Moscow.
Last year in November, Betuvax, a vaccine developer, raised about 100M rubles of venture investment within closed private placement. According to Sergey Masyuk, Director of Artgen Biotech, November 2024 did not seem to be the best time to raise investment for startups against the backdrop of a high key rate and accelerating inflation. “But with the support of Artgen Biotech Ecosystem and Skolkovo Foundation Betuvax managed to raise funds in record-breaking time — only in 1 month,” he noted.
Betuvax is specialized in sustainable antigen design for subunit vaccines aimed at allergic disease therapy and infectious and oncological disease prevention. It was established in 2020 and is a subsidiary of Artgen Biotech group (MOEX: ABIO).
Artgen Biotech is developing an internal ecosystem to accelerate biotech companies of the group and commercialize developments. Artgen Biotech Ecosystem consists of investment banking and IR teams assisting the companies of the group in fund raising. Artgen Biotech Ecosystem supported Genetico placement, which was the first IPO at the Russian market in 2023. Though the genetic research and development sector, where the company operates, is novel to the Russian market, the market showed interest in the issuer and the price for Genetico's shares showed annual growth by 180%. Toady Genetico's shares are listed at the IIM — the stock exchange sector for hi-tech companies possessing a significant growth potential.
In July 2023, Artgen Biotech's IR team helped RBT (Biotechnology Developments) raise 155M rubles within private placement at Rounds investment platform. RBT develops a platform to create virus vaccines based on hybrid surface proteins and adjuvant spherical particles. Coronavirus and influenza vaccines were previously developed on this platform as well as a combined pentavalent vaccine against influenza and coronavirus developed together with Nacimbio pharmaceutical holding.